Provider: Wright Reports
Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG's Board Proposes Martin Nicklasson To Succeed Chairman Werner Henrich
Basilea Pharmaceutica AG announced that its Board of Directors proposes Dr. Martin Nicklasson as designated non-executive Chairman of the Board of Directors to succeed Werner Henrich whose term will end at the upcoming AGM. Mr. Henrich will not stand for re-election as he will reach the statutory age limit for board members in 2013. Dr. Martin Nicklasson proposed for election to the Basilea Board of Directors.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation For Treatment Of zygomycosis By U.S.
- Basilea Pharmaceutica AG And Astellas Pharma Inc Reports Positive Topline Phase 3 Results For Antifungal Isavuconazole
- Basilea Pharmaceutica AG Announces Isavuconazole Orphan Drug Designation By U.S. FDA
- Basilea Pharmaceutica AG Issues FY 2013 Operating Loss Guidance-Conference Call
Latest Key Developments in Pharmaceuticals
- FDA approves Gilead Sciences Inc's Sovaldi the treatment of Chronic Hepatitis C
- Auxilium Pharmaceuticals Inc's drug to treat bent penis condition gets U.S. approval - Reuters
- Innovus Pharmaceuticals Inc receives product license approval of EjectDelay for premature ejaculation from Health Canada
- GSK and Theravance announce positive results from pivotal phase iii study for fluticasone furoate/vilanterol in asthma
- Share this
- Digg this